B+
Bull case
0%
Probability
Target price
$300.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
COR
CencoraCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The strongest post-print argument is that the market can look past a modest consensus miss because the company raised FY2026 adjusted EPS guidance to $17.65-$17.90, cited strong U.S. Healthcare Solutions operating-income growth, and showed OneOncology already helping mix and gross profit [#8-K-2026-05-06].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.9.
What can break
Acquisition financing materially increased debt: total debt rose to about $12.4 billion at March 31, 2026 from about $7.7 billion at September 30, 2025, raising interest-cost sensitivity after OneOncology [#10-Q-2026-05-06].
Momentum
70
Value
63
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $275.00 · Bull $300.00 · Bear $235.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $368.67
Why
Momentum70 · Δ7d +6.8
Value63 · Δ7d +0.9
Sentiment37 · Δ7d +3.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.9.
Contradictions & invalidation
- • Acquisition financing materially increased debt: total debt rose to about $12.4 billion at March 31, 2026 from about $7.7 billion at September 30, 2025, raising interest-cost sensitivity after OneOncology [#10-Q-2026-05-06].
- • Adjusted EPS and revenue both missed consensus in immediate post-earnings coverage, which can cap multiple expansion even after a guidance raise.
- • The main bear read is that the quarter still missed consensus on both EPS and revenue based on AP/Zacks figures, while the operational bridge includes lower manufacturer prices on some brands, weaker large mail-order sales from brand conversions, and the lingering effect of a lost oncology customer; that makes the raised guide more dependent on integration and mix staying favorable than the headline may suggest.
Catalyst clock
2026-05-14
Q2 print raised FY2026 adjusted EPS guide despite a small headline miss
Lead driver: Value · See fundamentals
Momentum
70
8% active weight
Current posture
7d trendImproving
Δ7d
+6.8
Δ21d
+21.6
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
-0.6
Sentiment
37
45% active weight
Current posture
7d trendImproving
Δ7d
+3.7
Δ21d
-13.5
Why this grade
Composite grade C. Momentum 69.6 / Value 63.0 / Sentiment 37.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$275.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$235.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$63.16B
Beta
0.68
Shares Out
190.83M
P/E (TTM)
42.9
P/S (TTM)
0.21
P/FCF (TTM)
23.88
Rev YoY
+5.1%
EPS YoY
+11.8%
Gross Margin
+3.6%
Op Margin
+1.3%
Net Debt
$4.94B
Current Ratio
0.93
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data